Gritstone bio - GRTS Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GRTS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRTS, but not buy additional shares or sell existing shares.
View GRTS analyst ratings or view top-rated stocks.

3 brokers have issued twelve-month target prices for Gritstone bio's shares. Their GRTS share price forecasts range from $2.00 to $7.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 57.2% from the stock's current price.
View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts.

Gritstone bio's stock was trading at $3.45 at the beginning of the year. Since then, GRTS shares have decreased by 7.8% and is now trading at $3.18.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our GRTS earnings forecast.

Gritstone bio, Inc. (NASDAQ:GRTS) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.16. The firm earned $2.61 million during the quarter, compared to analysts' expectations of $3 million. Gritstone bio had a negative trailing twelve-month return on equity of 67.00% and a negative net margin of 630.32%.

1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

(GRTS) raised $85 million in an initial public offering on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

Gritstone bio trades on the NASDAQ under the ticker symbol "GRTS."

Gritstone bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (6.19%), Assenagon Asset Management S.A. (2.33%), SkyOak Wealth LLC (0.16%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Erin Jones and Raphael Rousseau.
View institutional ownership trends.

Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GRTS stock can currently be purchased for approximately $3.18.

Gritstone bio (NASDAQ:GRTS) has a market capitalization of $265.12 million and generates $48.21 million in revenue each year. The company earns $-75,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

The company employs 193 workers across the globe.

Gritstone bio's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The official website for the company is www.gritstoneoncology.com. The company can be reached via phone at (510) 871-6100 or via email at ir@gritstone.com.